Antitrust Antitrust

Comment: UK regulator's Illumina-PacBio analysis shows it has no fear of uncertainty

By Nicholas Hirst and Flavia Fortes
  • 15 May 2020 10:05
  • 15 May 2020 10:05
Uncertainty about how fast-moving markets will develop won't stop UK merger regulators vetoing a deal if they find that, on balance, it could hurt competition.

That claim is one of the main takeaways of a bullish new paper by the UK merger watchdog reflecting on its reasons for pouring ice water

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Nicholas Hirst

Chief Correspondent

Nicholas covers EU merger review and antitrust investigations for Mlex in Brussels. He previously wrote about EU affairs for Politico Europe, European Voice and PaRR. After earning an LLM in European law from the College of Europe in Bruges, he spent a year working in the competition practice of a leading competition law firm in Brussels 2009-10. He graduated in modern European languages from Oxford University in 2006.

Flavia Fortes

Global Head of Mergers

Flavia writes about merger control, antitrust enforcement and litigation in the U.S. and Brazil. Before joining MLex, Flavia worked as an Antitrust Consultant in the Federal Trade Commission's Office of International Affairs and as a Research Fellow for the American Antitrust Institute. She has written on the intersection of antitrust law and intellectual property law in technology-driven and innovative markets.

Discover MLex

Stay on top of global regulatory developments

Latest News